<p>In part 1 of this 4-part series, Dr Paul Mather from the Perelman School of Medicine talks about how to select and manage patients with end-stage heart failure.</p>
<p>In part 1 of this 4-part series, Dr Paul Mather from the Perelman School of Medicine talks about how to select and manage patients with end-stage heart failure.</p>
Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Dr James Januzzi from Massachusetts General Hospital discusses the new consensus statement on heart failure, biomarker testing for diagnosing heart failure, and potential future treatments.
Dr James Januzzi from Massachusetts General Hospital discusses the new consensus statement on heart failure, biomarker testing for diagnosing heart failure, and potential future treatments.
<p>Dr Thomas Seck from Boehringer Ingelheim Pharmaceuticals discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.</p>
<p>Dr Thomas Seck from Boehringer Ingelheim Pharmaceuticals discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.</p>
Dr Seth Baum, president of the American Society for Preventive Cardiology, welcomes you to our new podcast series and leaves clinicians with a tip for gaining access to heart failure medication.
Dr William Boden from the VA New England Healthcare System discusses the key takeaways from his session about coronary stenting at the American Society for Preventive Cardiology's 2018 Congress on CVD...
